Parisian-based BrainVectis, a spin-off of Inserm, has received €1m in funding from private investors, which will be used to complete preclinical pharmacological tests.

The company is developing a gene therapy for Huntington's and Alzheimer's disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Upon completion, it will enter into the clinical trial phase for Huntington's and Alzheimer's disease in 2019 and 2021, respectively.

BrainVectis will restore cholesterol metabolism in the brain and aims to stop the progression of these neurodegenerative diseases.

"BrainVectis will restore cholesterol metabolism in the brain and aims to stop the progression of these neurodegenerative diseases."

The expression of CYP46A1, a key enzyme in cholesterol metabolism in these patients, is reduced.

To restore the normal function of the cholesterol pathway, BrainVectis plans to use a gene therapy vector to release CYP46A1 into the brains of these patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BrainVectis will use the funding to continue its research and complete its ongoing preclinical pharmacological studies.

The company is further planning a first clinical trial for Huntington's disease and subsequently for Alzheimer's disease.

Inserm director of research Dr Nathalie Cartier-Lacave said: “We are extremely grateful for the support of Paris Biotech Santé and the SATT IDF Innov who have helped us to create the company and given us an exclusive license for the patents required to develop the project.”

Huntington's and Alzheimer's diseases lead to deterioration in the function of nerve cells, specifically neurons, and cause severe cognitive and motor issues that ultimately lead to death.

BrainVectis aims to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain.